Skip to Content
Merck
  • JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1.

JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1.

Journal of immunology (Baltimore, Md. : 1950) (2009-01-07)
Dilip Kumar, Judith Hosse, Christine von Toerne, Elfriede Noessner, Peter J Nelson
ABSTRACT

The MAPKs ERK, JNK, and p38 control diverse aspects of the immune response, including regulation of cytotoxin biology in NK cells and CTL. The chemokine CCL5 is coreleased with the cytotoxins, perforin, the granzymes, and granulysin, during the lethal hit administered by cytotoxic CD8+ T cells (CTL). CCL5 expression is up-regulated relatively late in CTL coincident with their functional maturation 3-7 days after activation. Unlike T cells, NK cells have the ability to kill virally infected or transformed cells when directly isolated from the peripheral circulation. In this study, we show that in contrast to T cells, peripheral blood NK cells express CCL5 constitutively. The use of specific inhibitors of the JNK, ERK, and p38 MAPK pathways showed that the JNK pathway controls expression of CCL5 by NK cells. Promoter-reporter assays identified a compact region of the CCL5 promoter responsible for the constitutive transcription of CCL5 by NK cells. EMSA, chromatin immune precipitation, the use of heterologous promoters, and site-directed mutagenesis demonstrated that transcription in NK cells is largely controlled through binding of the transcription factor specificity protein 1 to a region -75 to -56 upstream of the site of transcriptional initiation. Specificity protein 1 expression, and in turn the constitutive expression of CCL5, was found to be controlled through constitutive activation of the JNK/MAPK pathway in peripheral blood NK cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-NFκB p52 Antibody, Upstate®, from rabbit
Sigma-Aldrich
LY 294002, LY294002, CAS 154447-36-6, is a cell-permeable, potent, reversible, and specific inhibitor of PI 3-kinase ((IC₅₀ = 1.4 µM). Acts on the ATP-binding site.
Sigma-Aldrich
PANSORBIN® Cells, Lyophilized
Roche
Hexanucleotide Mix, solution, pkg of 100 μL, sufficient for 50 labeling reactions
Sigma-Aldrich
PMA, for use in molecular biology applications, ≥99% (HPLC)
Sigma-Aldrich
Gö 6983, A potent, cell-permeable, reversible, and ATP-competitive inhibitor of protein kinase C (PKC) that inhibits several PKC isozymes.
Sigma-Aldrich
Anti-Sp1 Antibody, Upstate®, from rabbit
Sigma-Aldrich
Anti-NFκB p65 Antibody, CT, Upstate®, from rabbit
Roche
DNA, MB-grade, from fish sperm
Sigma-Aldrich
Ionomycin calcium salt, Ready Made Solution, from Streptomyces conglobatus, 1 mM in DMSO